Measurable Residual Disease Negativity at a High in Leukemia Trial

The CLARITY trial looked at measurable residual disease negativity in 54 patients with relapsed or refractory chronic lymphocytic leukemia who received ibrutinib in combination with venetoclax.

Source: CancerNetwork - August 20, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news